Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer
Vishnu Prasath(Johns Hopkins University), Bhuvaneswari Ramaswamy(The Ohio State University), Mahmoud Abdel‐Rasoul(The Ohio State University), G. Thomas Budd(Cleveland Clinic), Cynthia Timmers(Cancer Genetics (United States)), Ewa Mrózek(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Erin Macrae(McGill University), Gary L. Johnson(University of Colorado Hospital), Daniel G. Stover(Harvard University), Charles L. Shapiro(Tisch Hospital), Helen X. Chen(National Cancer Institute), William E. Carson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Charles M. Perou(University of North Carolina at Chapel Hill), Rachel M. Layman(The University of Texas MD Anderson Cancer Center), Claudine Isaacs(Georgetown University), Mark Vater(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Andrew Poklepovic(Virginia Commonwealth University), Claire Dees(University of North Carolina at Chapel Hill), Maryam B. Lustberg(Yale Cancer Center), Robert Wesolowski(The Ohio State University), H. Boutrid(The Ohio State University Wexner Medical Center), Miguel A. Villalona‐Calero(University of California, Irvine), Kristyn Glover(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Lyndsay N. Harris(National Institutes of Health)
Cited by 12
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k